PYXS
NASDAQPyxis Oncology Inc.
Price$1.70-0.53 (-23.77%)
2026-07-162026-10-16
News · 26 weeks40+25%
2026-04-192026-10-11
Mix2490d
- SEC Filings11(46%)
- Other4(17%)
- Insider4(17%)
- Offering3(13%)
- Analyst1(4%)
- Leadership1(4%)
Latest news
25 items- SECSEC Form PRE 14A filed by Pyxis Oncology Inc.PRE 14A - Pyxis Oncology, Inc. (0001782223) (Filer)
- INSIDERAmendment: SEC Form 4/A filed by Pyxis Oncology Inc.4/A - Pyxis Oncology, Inc. (0001782223) (Issuer)
- INSIDERLarge owner Gordonmd Global Investments Lp bought 5,517,000 shares (SEC Form 4)4 - Pyxis Oncology, Inc. (0001782223) (Issuer)
- PRPyxis Oncology Announces Closing of Up to $282.6 Million Public OfferingBOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it closed its previously announced registered public offering (the "Offering") on October 1, 2026. The Offering generated approximately $110.0 million in upfront gross proceeds, before deducting underwriting discounts and commissions and other offering expenses. The Offering consisted of 36,047,919 shares of common stock at a public offering price of $2.90 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,883,121 shares of common stock at a public offer
- SECPyxis Oncology Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K - Pyxis Oncology, Inc. (0001782223) (Filer)
- SECSEC Form 424B5 filed by Pyxis Oncology Inc.424B5 - Pyxis Oncology, Inc. (0001782223) (Filer)
- PRPyxis Oncology Announces Pricing of Up to $282.6 Million Public OfferingBOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced the pricing of its previously announced registered public offering (the "Offering") of 36,047,919 shares of its common stock, or in lieu of common stock to certain investors, 1,883,121 pre-funded warrants to purchase shares of common stock, and accompanying common warrants to purchase 49,310,352 shares of common stock at an exercise price of $3.50. The combined public offering price for each share of common stock and accompanying common warrant is $2.90, and the combined public offering price for each
- SECSEC Form 424B5 filed by Pyxis Oncology Inc.424B5 - Pyxis Oncology, Inc. (0001782223) (Filer)
- PRPyxis Oncology Announces Proposed Public OfferingBOSTON, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it has commenced a registered public offering (the "Offering") of (i) shares of its common stock, or in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock, and (ii) accompanying common warrants to purchase shares of common stock. Each share of common stock and each pre-funded warrant will be sold together with a common warrant to purchase one share of common stock. The common warrants will become exercisable only upon approval by the Company's stock
- SECSEC Form 424B5 filed by Pyxis Oncology Inc.424B5 - Pyxis Oncology, Inc. (0001782223) (Filer)
- SECPyxis Oncology Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Pyxis Oncology, Inc. (0001782223) (Filer)
- PRPyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)MICVO demonstrated rapid and deep responses, with a 36% confirmed objective response rate (cORR) and 94% disease control rate (DCR), with clinical activity observed across HPV status and prior-treatment subgroups Substantial survival outcomes include median progression-free survival (mPFS) of 6.2 months and 12-month overall survival (OS) probability of 79%, with clinical activity observed across HPV status and prior-treatment subgroups No new safety signals observed; tolerability profile expected & consistent with prolonged auristatin exposure; dose capping reduced frequency and severity of adverse events in high body weight patients MICVO potentially addresses significant unmet need in 2
- PRPyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it will host a live webcast on September 9, 2026 at 7:30 a.m. Eastern Time to present updated clinical data from its ongoing Phase 1 monotherapy study evaluating micvotabart pelidotin (MICVO) in patients with second-line and beyond (2L+) recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The presentation will include the scientific rationale for Pyxis Oncology’s novel ADC, MICVO; implications of the evolving treatment landscape in R/M HNSCC; detailed analyses of patients tre
- INSIDERSEC Form 4 filed by CEO & Chairman of the Board Civik Thomas4 - Pyxis Oncology, Inc. (0001782223) (Issuer)
- SECPyxis Oncology Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Pyxis Oncology, Inc. (0001782223) (Filer)
- PRPyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the BoardJohn Flavin, Co-Founder and Founding Chairman, to serve as Lead Independent Director of the Board Leadership transition reflects continued focus on advancing MICVO through key clinical milestones BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, announced today that its Board of Directors has appointed Thomas Civik as Chief Executive Officer and Chairman of the Board, effective as of September 4, 2026. Mr. Civik has served as Interim Chief Executive Officer since February 2026 and as a member of Pyxis Oncology’s Board of Directors since 2021. In connection with M
- PRPyxis Oncology to Participate in Upcoming Investor ConferencesBOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Tom Civik, Interim Chief Executive Officer and Director of Pyxis Oncology, will participate in fireside chats at three upcoming conferences. Wells Fargo 21st Annual Healthcare Conference in Boston, MA on Thursday, September 10, 2026, at 10:15 a.m. ET.2026 Cantor Global Healthcare Conference in New York, NY on Friday, September 11, 2026, at 10:55 a.m. ET.H.C. Wainwright 28th Annual Global Investment Conference in New York, NY on Monday, September 14, 2026, at 9:30 a.m. ET. Live webcasts and repl
- SECSEC Form EFFECT filed by Pyxis Oncology Inc.EFFECT - Pyxis Oncology, Inc. (0001782223) (Filer)
- INSIDERSEC Form 4 filed by Director Dupont Jakob4 - Pyxis Oncology, Inc. (0001782223) (Issuer)
- SECSEC Form S-3 filed by Pyxis Oncology Inc.S-3 - Pyxis Oncology, Inc. (0001782223) (Filer)
- SECSEC Form 10-Q filed by Pyxis Oncology Inc.10-Q - Pyxis Oncology, Inc. (0001782223) (Filer)
- SECPyxis Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Pyxis Oncology, Inc. (0001782223) (Filer)
- PRPyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical MilestonesUpdated data from the MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track to be reported in Fall 2026; update to include detailed analyses of patients treated at or below a dose cap Updated data from the MICVO Phase 1/2 combination study with pembrolizumab in 1L R/M HNSCC on track to be reported in the fourth quarter of 2026 Completed private placement financing for up to $114 million, providing approximately $50 million in upfront gross proceeds to support additional patient follow-up Upfront proceeds from the private placement, together with existing cash, extended the Company’s cash runway into the second quarter of 2027 BOSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Pyxis
- ANALYSTWells Fargo initiated coverage on Pyxis Oncology with a new price targetWells Fargo initiated coverage of Pyxis Oncology with a rating of Overweight and set a new price target of $12.00
- INSIDERNew insider Gordonmd Global Investments Lp claimed ownership of 10,024,909 shares (SEC Form 3)3 - Pyxis Oncology, Inc. (0001782223) (Issuer)
PYXS FAQ
7 questionsWhat does Pyxis Oncology Inc. do?
Pyxis Oncology, Inc., a preclinical stage biotechnology company, engages in the development of antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies to treat cancers. Its preclinical products pipeline includes PYX-201, a site-specific investigational ADC targeting onco-fetal fibronectin extradomain-B for the treatment of non-small cell lung cancer; PYX-202, a site-specific investigational ADC targeting delta like non-canonical notch ligand 1 to treat small cell lung cancer, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational site-specific ADC...Where does PYXS stock trade?
Pyxis Oncology Inc. (PYXS) is listed on NASDAQ.What sector and industry is PYXS in?
Pyxis Oncology Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Pyxis Oncology Inc. go public?
Pyxis Oncology Inc. (PYXS) completed its IPO in 2021.What are analysts saying about PYXS?
Pyxis Oncology Inc. has had 8 recent analyst actions on file. The most recent action was from Wells Fargo: Overweight with a $1200.00 price target on 2026-08-03. Recent price targets range from $500.00 to $1300.00.What companies are similar to PYXS?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare PYXS side-by-side with any of them on Quantisnow.How can I track PYXS on Quantisnow?
Quantisnow aggregates Pyxis Oncology Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PYXS to receive live email and push alerts on every new disclosure.